Which physicians are affected most by medicaid preferred drug lists for statins and antihypertensives?

PharmacoEconomics

Volumn 24, Issue SUPPL.3, 2006, Pages 27-40

  Ketcham, Jonathan D ^a   Epstein, Andrew J ^b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CLINICAL PRACTICE; ECONOMICS; EPIDEMIOLOGY; FEMALE; HUMAN; MALE; MEDICAID; METHODOLOGY; MIDDLE AGED; PHARMACOECONOMICS; PUBLICATION; STANDARD; STATISTICS; TIME;

ADULT; ANTIHYPERTENSIVE AGENTS; ECONOMICS, PHARMACEUTICAL; FEMALE; FORMULARIES; HEALTH CARE SURVEYS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICAID; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; TIME FACTORS;

EID: 34250310906     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/00019053-200624003-00003     Document Type: Article

References (25)

1. Centers for Medicare and Medicaid Services. 2004 Medicaid managed care enrollment report [online]. Available from URL: http://www.cms.hhs.gov/ MedicaidDataSourcesGen Info/downloads/mmcer04.pdf [Accessed 2006 October 27].
2. Centers for Medicare and Medicaid Services. National health expenditures by type of service and source of funds: calendar years 2004-1960 [online]. Available from URL: http://www.cms.hhs.gov/NationalHealth ExpendData/02- NationalHealthAccountsHistorical.asp [Accessed 2006 October 27].
3. Smith C, Cowan C, HeftierS, et al. National health spending in 2004: recent slowdown led by prescription drug spending. Health Aff 2006; 25 (1): 186-96 (Pubitemid 43202441)
4. Center for Medicaid and State Operations. 2004. Letter to state Medicaid directors September 9, 2004. [online] Available from URL: http://www.nasmd.org/ Multi-State-pool-letter.pdf [Accessed 2006 October 27].
5. MacKinnon NJ, Kumar R. Prior authorization programs: a critical review of the literature. J Manag Care Pharm 2001; 74: 297-303
6. Fischer MA, Schneeweis S, Avorn J, et al. Medicaid priorauthorization programs and the use of cyclooxygenase-2 inhibitors. N Engl J Med 2004; 351: 2187-94 (Pubitemid 39507631)
7. Bukstein DA, Cheriayil GA, Gepner AD, et al. The economic burden associated with prior authorizations in an allergist office. Allergy Asthma Proc 2006; 27 (2): 119-22 (Pubitemid 43700861)
8. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff 2004 Jan/Feb; 23 (1): 135-46 (Pubitemid 39115293)
9. Headen A, Masia N. Exploring the potential link between Medicaid access restrictions, physician location, and health disparities. Am J Manag Care 2005; 11: SP21-26
10. Cunningham PJ. Medicaid cost containment and access to prescription drugs. Health Aff 2005; 24 (3): 780-9
11. Sloan F, Mitchell J, Cromwell J. Physician participation in state Medicaid programs. J Hum Resourc 1978; 13 Suppl.:211-245
12. Adams K. Factors affecting physician preventive care to Medicaid children. Health Care Financ Rev 2001; 22 (4): 9-26
13. Perloff JD, Kletke P, Fossett JW. Which physicians limit their Medicaid participation and why. Health Serv Res 2006; 30 (1): 7-26
14. Glied S, Zivin JG. How do doctors behave when some (but not all) of their patients are in managed care? J Health Econ 2001; 21: 337-53 (Pubitemid 34143150)
15. Wang YR, Pauly MV, Lin YA. Impact of Maine's Medicaid drug formulary change on non-Medicaid markets: spillover effects of a restrictive drug formulary. Am J Manag Care 2003; 9: 686-96 (Pubitemid 37345198)
16. Wang YR, Pauly MV. Spillover effects of restrictive drug formularies on physician prescribing behavior: evidence from Medicaid. J Econ Manag Strat 2005; 14 (3): 755-73 (Pubitemid 41239677)
17. Virabhak S, Shinogle JA. Physicians' prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana. Am J Manag Care 2005; 11: SP14-20
18. Fossett JW, Peterson JA. Physician supply and Medicaid participation. Med Care 1989; 27 (4): 386-96
19. Polsky D, Kletke PR, Wozniak GD, Escarce JJ. HMO penetration and the geographic mobility of practicing physicians. J Health Econ 2000; 19 (5): 793-809
20. Centers for Medicare and Medicaid Services. 2006 Medicare trustees report [online]. Available from URL: http://www.cms.hhs.gov/apps/media/press/release. asp? Counter=1846 [Accessed 2006 October 27]
21. Hoadley JE, Hargrave E, Cubanski J, et al. An in-depth examination of formularies and other features of Medicare drug plans, Kaiser Family Foundation. Available from URL: http://www.kff.org/medicare/upload/7489. pdf [Accessed 2006 October 27]
22. Murawski MM, Abdelgawad T. Exploration of the impact of preferred drug lists on hospital and physician visits and the costs to Medicaid. Am J Manag Care 2005; 11: SP35-42
23. Smalley WE, Griffen MR, Fought RL, et al. Effect of a prior-authorization requirement on the use of nonsteroidal anti-inflammatory drugs by Medicaid patients. New Engl J Med 1995; 332: 1612-17
24. Wilson J, Axelsen K, Tang S. PDL implementation increases chances that Medicaid patients discontinue filling prescriptions for antihypertensives. Am J Manag Care 2005; 11: SP27-34
25. Särndal CE, Swensson B, Wretman J. Model assisted survey sampling. New York: Springer-Verlag, 1992